From post-war reconstruction to the twenty-first century – ophthalmic pathology in Freiburg 1945–2015: review of 39,256 surgical specimens from various topographical regions collected over 71 years at a large German tertiary eye care centre

Table 22 Comparison of malignant eyelid tumours

Author	Aurora, Blodi [18]	Rohrbach et al. [16]	Spraul, Grossniklaus [17]	Welch, Duke [19]	Font et al. [20]	Tesluk [21]	Deprez, Uffer [22]	Domingo et al. [23]	Current study
Region	Iowa	Tübingen	Atlanta	Baltimore	Pasadena	Philadelphia	Lausanne	Manila	Freiburg
Time period	1932–1969	1940–1990 ¹⁾	1941–1995	1952–1956	1970–2000	1980–1982	1989–2007	2003–2012	1945–2015
Number	n = 214	n = 91	n = 172	n = 88	n = 594	n = 125	n = 1,096	n = 170	n = 4,396
Basal cell carcinoma (AMP)	80.4%	68%	59.9%	77%	69%	82.4%	70%	30.6%	86%
Squamous cell carcinoma (EMP)	7.0%	25%	18.6%	19%	5%	2.4%	6.1%	17.1%	6.0%
Sebaceous gland carcinoma (EMP)	3.2%	²⁾	15.1%	1%	14%	6.4%	2.6%	30.6%	1.7%
Lymphoma (EMP)	1.8%	-	1.2%	-	3%	2.4%	-	6.5%	1.1%
Metastasis (EMP)	1.4%	²⁾	1.2%	-	1%	-	0.4%	1.2%	0.3%
Merkel cell carcinoma (EMP)	-	-	-	-	< 1%	-	0.4%	-	0.1%
Other malignant eyelid tumour	6.0% ³⁾	6.6% ⁴⁾	4.1% ⁵⁾	2.2% ⁶⁾	8%	6.2% ⁷⁾	20% ⁸⁾	13.6% ⁹⁾	4.4%

Relative frequencies of malignant tumours of the eyelid with associated diagnoses and comparison with eight other studies. Percentages may not total 100 due to rounding
¹⁾ Specimens collected and diagnosed in 1940, 1960, 1980, 1990 [16]
²⁾ Not specified separately, included in “other malignant lid tumour”
³⁾ Includes melanoma (5.1%), Bowen’s disease (0.5%) and adenocarcinoma of gland of Moll (0.5%) [18]
⁴⁾ Includes sebaceous gland carcinoma, malignant melanoma, metastasis [16]
⁵⁾ Includes melanoma (2.9%) and carcinoma, poorly differentiated (1.2%) [17]
⁶⁾ Includes carcinoma in situ [19]
⁷⁾ Includes malignant melanoma (5.4%) and carcinoma in situ (0.8%) [21]
⁸⁾ Includes actinic keratosis (18%), squamous cell carcinoma in situ (1.3%), lentigo maligna (0.5%), lentigo maligna melanoma (0.2%) and Kaposi sarcoma 0.1%) [22]
⁹⁾ Includes melanoma (11.8%), malignant pilar structure tumours (1.2%), mucoepidermoid carcinoma (0.6%) [23]

ISSN: 1471-2415